Terms ending in 2030
Every in-force patent on DCB-USA LLC's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,241,608 | Treating Allergy with Detoxified E. Coli Heat-Labile Enterotoxin In force · High confidence | Development Center for Biotechnology | In force | High confidence | |
| US 8,119,683 | Aryl Substituted Sulfonamide Compounds and Their Use as Anticancer Agents In force · High confidence | Taipei Medical University, DCB-USA LLC and National Health Research Institutes | In force | High confidence | |
| US 9,315,491 | Novel Pyrimidine Compounds as Mtor and PI3K Inhibitors In force · High confidence | Development Center for Biotechnology | In force | High confidence | |
| US 9,801,888 | Novel Pyrimidine Compounds as Mtor and PI3K Inhibitors In force · High confidence | Development Center for Biotechnology | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by DCB-USA LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.